Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

M Trigueros, E Pradenas, D Palacín… - Age and …, 2022 - academic.oup.com
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …
被引用次数：11 相关文章
[PDF] oup.com

[PDF][PDF] Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

M Trigueros, E Pradenas, D Palacín… - Age and …, 2022 - academic.oup.com
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

BC Sala, E Pradenas, D Palacín… - Age and …, 2022 - portalrecerca.uab.cat
SARS-CoV-2 vaccination is the most effective strategy to protect older residents of long-term
care facilities (LTCF) against severe COVID-19, but primary vaccine responses are less …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.

E Pradenas, D Palacín, F Muñoz-López… - Age & …, 2022 - search.ebscohost.com
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Reduced humoral response 3 months following BNT162B2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.

M Trigueros, E Pradenas, D Palacín, F Muñoz-López… - 2022 - cabidigitallibrary.org
Abstract Background: SARS-CoV-2 vaccination is the most effective strategy to protect older
residents of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine …
[HTML] nih.gov

[HTML][HTML] Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

E Pradenas, D Palacín, F Muñoz-López… - Age and …, 2022 - ncbi.nlm.nih.gov
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.

M Trigueros, E Pradenas, D Palacín… - Age and …, 2022 - europepmc.org
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

E Pradenas, D Palacín, F Muñoz-López… - Age and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

E Pradenas, D Palacín, F Muñoz-López… - Age and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.

M Trigueros, E Pradenas, D Palacín… - Age and …, 2022 - europepmc.org
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …